Disease · MONDO_0005607
Targets20
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 20
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | 7 | Beta-2 adrenergic receptor agonist | Approval | https://conductscience.org/library/genes/154 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 6 | Muscarinic acetylcholine receptor M3 antagonist | Approval | https://conductscience.org/library/genes/1131 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Approval | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PDE4A | Phosphodiesterase 4 | 3 | Phosphodiesterase 4 inhibitor | Approval | https://conductscience.org/library/genes/5141 | Drugs and targets |
| PDE4B | Phosphodiesterase 4 | 3 | Phosphodiesterase 4 inhibitor | Approval | https://conductscience.org/library/genes/5142 | Drugs and targets |
| PDE4C | Phosphodiesterase 4 | 3 | Phosphodiesterase 4 inhibitor | Approval | https://conductscience.org/library/genes/5143 | Drugs and targets |
| PDE4D | Phosphodiesterase 4 | 3 | Phosphodiesterase 4 inhibitor | Approval | https://conductscience.org/library/genes/5144 | Drugs and targets |
| ADORA1 | Adenosine receptor | 1 | Adenosine receptor antagonist | Approval | https://conductscience.org/library/genes/134 | Drugs and targets |
| ADORA2A | Adenosine receptor | 1 | Adenosine receptor antagonist | Approval | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine receptor | 1 | Adenosine receptor antagonist | Approval | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADORA3 | Adenosine receptor | 1 | Adenosine receptor antagonist | Approval | https://conductscience.org/library/genes/140 | Drugs and targets |
| CFTR | Cystic fibrosis transmembrane conductance regulator | 1 | Cystic fibrosis transmembrane conductance regulator activator; Cystic fibrosis transmembrane conductance regulator positive modulator | Phase 2 | https://conductscience.org/library/genes/1080 | Drugs and targets |
| CHRM1 | Muscarinic acetylcholine receptor M1 | 1 | Muscarinic acetylcholine receptor M1 antagonist | Approval | https://conductscience.org/library/genes/1128 | Drugs and targets |
| MARCKS | Myristoylated alanine-rich C-kinase substrate | 1 | Myristoylated alanine-rich C-kinase substrate inhibitor | Phase 2 | https://conductscience.org/library/genes/4082 | Drugs and targets |
| PDE3A | Phosphodiesterase 3 | 1 | Phosphodiesterase 3 inhibitor | Approval | https://conductscience.org/library/genes/5139 | Drugs and targets |
| PDE3B | Phosphodiesterase 3 | 1 | Phosphodiesterase 3 inhibitor | Approval | https://conductscience.org/library/genes/5140 | Drugs and targets |
| SCNN1A | Amiloride-sensitive sodium channel, ENaC mRNA | 1 | Amiloride-sensitive sodium channel, ENaC mRNA antisense inhibitor | Phase 2 | https://conductscience.org/library/genes/6337 | Drugs and targets |
| SCNN1B | Amiloride-sensitive sodium channel, ENaC mRNA | 1 | Amiloride-sensitive sodium channel, ENaC mRNA antisense inhibitor | Phase 2 | https://conductscience.org/library/genes/6338 | Drugs and targets |
| SCNN1G | Amiloride-sensitive sodium channel, ENaC mRNA | 1 | Amiloride-sensitive sodium channel, ENaC mRNA antisense inhibitor | Phase 2 | https://conductscience.org/library/genes/6340 | Drugs and targets |
| TNF | Tumor necrosis factor | 1 | TNF-alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/7124 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005607/targets